ACIU — AC Immune SA Cashflow Statement
0.000.00%
Last trade - 00:00- $164.67m
- -$28.69m
- CH₣27.31m
- 50
- 50
- 45
- 46
Annual cashflow statement for AC Immune SA, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -61.9 | -73 | -70.8 | -54.2 | -50.9 |
| Depreciation | |||||
| Non-Cash Items | 5.28 | -1.47 | 3.67 | 6.35 | 5.65 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.84 | 6.37 | -8.84 | -14.7 | 109 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -59.5 | -65.7 | -73.6 | -60.4 | 65.8 |
| Capital Expenditures | -1.71 | -2.63 | -1.24 | -0.801 | -0.576 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 30 | -51 | 25 | 66.4 | -105 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 28.3 | -53.7 | 23.8 | 65.6 | -105 |
| Financing Cash Flow Items | — | -0.006 | -0.784 | 0 | -0.548 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.803 | 40.7 | -1.35 | 43.3 | -1.12 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -32.7 | -78.7 | -50.6 | 46.9 | -42.2 |